Showing results (1-10 of 20) with videos related to
Sort By:
Pageof 2
Journal of Clinical Pharmacology|June 14, 2005
Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trialChee M Ng, Rene Bruno, Dan Combs, et al.Journal of Pharmacokinetics and Pharmacodynamics|September 21, 2019
A modeling and simulation-based assessment of the impact of confounding factors on the readout of a sildenafil survival trial in pulmonary arterial hypertensionPascal Chanu, Xiang Gao, Rene Bruno, et al.Journal of Clinical Pharmacology|April 19, 2017
Modeling and Simulation of Pivotal Clinical Trials Using Linked Models for Multiple Endpoints in Chronic Obstructive Pulmonary Disease With RoflumilastAxel Facius, Andreas Krause, Laurent Claret, et al.Journal of Pharmacokinetics and Pharmacodynamics|September 1, 2020
Longitudinal analysis of organ-specific tumor lesion sizes in metastatic colorectal cancer patients receiving first line standard chemotherapy in combination with anti-angiogenic treatmentFrancois Mercier, Marion Kerioui, Solène Desmée, et al.BMC Cancer|July 15, 2016
Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validationKelong Han, Laurent Claret, Alan Sandler, et al.Cancer Chemotherapy and Pharmacology|July 23, 2015
Modeling and simulations relating overall survival to tumor growth inhibition in renal cell carcinoma patientsLaurent Claret, Francois Mercier, Brett E Houk, et al.Cancer Chemotherapy and Pharmacology|January 22, 2008
Clinical pharmacokinetics of bevacizumab in patients with solid tumorsJian-Feng Lu, Rene Bruno, Steve Eppler, et al.Cancer Chemotherapy and Pharmacology|May 4, 2005
Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancerRene Bruno, Carla B Washington, Jian-Feng Lu, et al.Cancer Immunology Research|December 3, 2017
Report on the Third FDA-AACR Oncology Dose-Finding WorkshopLeisha A Emens, Rene Bruno, Eric H Rubin, et al.Cancer Chemotherapy and Pharmacology|April 28, 2018
Comparison of tumor size assessments in tumor growth inhibition-overall survival models with second-line colorectal cancer data from the VELOUR studyLaurent Claret, Christina Pentafragka, Sanja Karovic, et al.Pageof 2